BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36017694)

  • 1. The implications from the interplay of neoadjuvant chemoradiotherapy and the immune microenvironment in rectal cancer.
    Shi M; Chen Y; Ji D
    Future Oncol; 2022 Sep; 18(28):3229-3244. PubMed ID: 36017694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 3. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 4. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in the prediction of the efficacy and sensitivity of neoadjuvant chemoradiotherapy in rectal cancer].
    Ji Q; Li YF; Wu T
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):392-397. PubMed ID: 31054555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 7. Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    Markovina S; Youssef F; Roy A; Aggarwal S; Khwaja S; DeWees T; Tan B; Hunt S; Myerson RJ; Chang DT; Parikh PJ; Olsen JR
    Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):417-426. PubMed ID: 28871992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade.
    He L; Jin M; Jian D; Yang B; Dai N; Feng Y; Xiao H; Wang D
    Front Immunol; 2022; 13():955187. PubMed ID: 36238279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of total neoadjuvant therapy consisting of consolidation chemotherapy on locally advanced rectal cancer survival.
    Zhang H; Li G; Cao K; Zhai Z; Wei G; Qu H; Wang Z; Han J
    Int J Colorectal Dis; 2022 Jul; 37(7):1657-1668. PubMed ID: 35716183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
    Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 13. [Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].
    Shu Z; Fang S; Ding Z; Mao D; Pang P; Gong X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1051-1058. PubMed ID: 30269327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the tumor microenvironment and identification of spatially predictive biomarkers associated with beneficial neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Zhang S; Li N; Wang F; Liu H; Zhang Y; Xiao J; Qiu W; Zhang C; Fan X; Qiu M; Li M; Tang H; Fan S; Wang J; Luo H; Li X; Lin J; Huang Y; Liang L
    Pharmacol Res; 2023 Nov; 197():106974. PubMed ID: 37898442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of carcinoembryonic antigen combined with carbohydrate antigen 19-9 following neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Zheng Z; Wang X; Lu X; Huang Y; Chi P
    Colorectal Dis; 2021 Sep; 23(9):2320-2330. PubMed ID: 33900006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, Safety, and Outcomes of Neoadjuvant Chemoradiotherapy With Capecitabine for Patients Aged ≥ 70 Years With Locally Advanced Rectal Cancer.
    Jacobs L; van der Vlies E; Ten Bokkel Huinink D; Bloemendal H; Intven M; Smits AB; Weusten BLAM; Siersema PD; van Lelyveld N; Los M
    Clin Colorectal Cancer; 2018 Sep; 17(3):179-186. PubMed ID: 29661620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer.
    Sclafani F; Cunningham D
    Future Oncol; 2014 Nov; 10(14):2243-57. PubMed ID: 25471037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center.
    Zhou J; Qiu H; Lin G; Xiao Y; Wu B; Wu W; Sun X; Lu J; Zhang G; Xu L; Liu Y
    Int J Colorectal Dis; 2016 Jun; 31(6):1163-8. PubMed ID: 27044403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.